1. Home
  2. INAB vs TGE.WS Comparison

INAB vs TGE.WS Comparison

Compare INAB & TGE.WS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$0.75

Market Cap

11.8M

Sector

Health Care

ML Signal

HOLD

TGE.WS

The Generation Essentials Group Warrants each whole warrant exercisable for one Class A Ordinary Share

N/A

Current Price

$0.04

Market Cap

0.0

ML Signal

N/A

Company Overview

Basic Information
Metric
INAB
TGE.WS
Founded
2016
N/A
Country
United States
Employees
N/A
166
Industry
Biotechnology: Pharmaceutical Preparations
Newspapers/Magazines
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
11.8M
N/A
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
INAB
TGE.WS
Price
$0.75
$0.04
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
★ $7.00
N/A
AVG Volume (30 Days)
★ 69.2K
700.0
Earning Date
11-05-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.72
$0.04
52 Week High
$2.73
$0.05

Technical Indicators

Market Signals
Indicator
INAB
TGE.WS
Relative Strength Index (RSI) 32.88 N/A
Support Level N/A N/A
Resistance Level $1.50 N/A
Average True Range (ATR) 0.08 0.00
MACD -0.01 0.00
Stochastic Oscillator 9.62 0.00

Price Performance

Historical Comparison
INAB
TGE.WS

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

About TGE.WS The Generation Essentials Group Warrants each whole warrant exercisable for one Class A Ordinary Share

The Generation Essentials Group is a media and entertainment company. Its publications L'Officiel and The Art Newspaper publish print editions in a total of nearly 28 countries and territories and digital contents. It operate in the movie production sector having produced various Asia-focused movies. It operate in three operating segments: media and entertainment segment, hotel operations, hospitality and VIP services segment and strategic investment segment. Key revenue is generated from strategic investment segment that is engage in proprietary investments and management of portfolio, including listed and unlisted equity shares investments and movie income right investments.

Share on Social Networks: